Oryzon Genomics S.A. (BME:ORY)

Market Cap	221.69M +18.3%
Revenue (ttm)	10.93M +48.6%
Net Income	-2.61M
EPS	-0.03
Shares Out	77.51M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	133,274
Average Volume	437,089
Open	2.890
Previous Close	2.860
Day's Range	2.810 - 2.890
52-Week Range	2.430 - 4.020
Beta	0.36
RSI	41.20
Earnings Date	Feb 27, 2026

About Oryzon Genomics

Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system) disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 47
• Stock Exchange: Madrid Stock Exchange
• Ticker Symbol: ORY

Financial Performance

In 2025, Oryzon Genomics's revenue was 10.93 million, an increase of 48.59% compared to the previous year's 7.36 million. Losses were -2.61 million, -27.18% less than in 2024.